Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$6.29
-2.5%
$5.74
$3.79
$14.60
$322.91M-0.91978,671 shs592,013 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$2.25
-2.2%
$1.84
$1.23
$4.92
$85.98M-0.14925,210 shs317,557 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.60
-6.6%
$29.22
$23.15
$91.99
$11.43B1.838.23 million shs16.27 million shs
Prothena Corporation plc stock logo
PRTA
Prothena
$6.81
-0.9%
$5.95
$4.32
$23.66
$366.56M-0.03765,312 shs840,982 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.48%-10.40%+26.05%+19.13%+6.07%
Metagenomi, Inc. stock logo
MGX
Metagenomi
-2.17%-7.41%+39.75%+39.75%-42.01%
Moderna, Inc. stock logo
MRNA
Moderna
-6.63%-19.18%-8.85%-0.04%-76.85%
Prothena Corporation plc stock logo
PRTA
Prothena
-0.87%+1.95%+7.75%-19.88%-70.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.1933 of 5 stars
3.62.00.00.01.41.70.6
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.43 of 5 stars
3.54.00.00.00.61.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.4709 of 5 stars
4.01.00.04.63.02.51.3
Prothena Corporation plc stock logo
PRTA
Prothena
3.1085 of 5 stars
4.22.00.00.01.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.20
Buy$22.00249.76% Upside
Metagenomi, Inc. stock logo
MGX
Metagenomi
3.00
Buy$13.00477.78% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.1167.07% Upside
Prothena Corporation plc stock logo
PRTA
Prothena
2.33
Hold$31.50362.56% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, PRTA, and CADL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$26.00 ➝ $25.00
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$23.00
6/20/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
$52.29M1.61N/AN/A$6.28 per share0.36
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.30N/AN/A$28.33 per share0.97
Prothena Corporation plc stock logo
PRTA
Prothena
$137.94M2.66N/AN/A$9.05 per share0.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$78.06M-$2.11N/AN/AN/A-172.21%-31.21%-22.21%8/13/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%N/A
Prothena Corporation plc stock logo
PRTA
Prothena
-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/4/2025 (Estimated)

Latest MGX, MRNA, PRTA, and CADL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.62N/AN/AN/A$7.72 millionN/A
8/12/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17N/AN/AN/AN/AN/A
8/4/2025Q2 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$1.06N/AN/AN/A$5.36 millionN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
5/13/2025Q1 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million
5/8/2025Q1 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
4.64
4.64
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
5.85
5.85
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
9.00
9.00

Institutional Ownership

CompanyInstitutional Ownership
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Prothena Corporation plc stock logo
PRTA
Prothena
97.08%

Insider Ownership

CompanyInsider Ownership
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Metagenomi, Inc. stock logo
MGX
Metagenomi
17.80%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Prothena Corporation plc stock logo
PRTA
Prothena
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million41.79 millionOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.38 million30.73 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Prothena Corporation plc stock logo
PRTA
Prothena
13053.83 million48.88 millionOptionable

Recent News About These Companies

Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday
Prothena (PRTA) Projected to Post Earnings on Monday
Prothena Announces Corporate Restructuring
PRTA Prothena Corporation plc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$6.29 -0.16 (-2.48%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.28 0.00 (-0.08%)
As of 08/1/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$2.25 -0.05 (-2.17%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.22 -0.02 (-1.11%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.60 -1.96 (-6.63%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$27.72 +0.13 (+0.45%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Prothena stock logo

Prothena NASDAQ:PRTA

$6.81 -0.06 (-0.87%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.80 0.00 (-0.07%)
As of 08/1/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.